The story

Amylin was discovered in 1987 by Garth Cooper at Oxford, and the same year by Per Westermark in Sweden, as the protein that forms deposits in the pancreas of people with type 2 diabetes. Its first drug copy, pramlintide, needed three injections a day. At Novo Nordisk in Denmark, Thomas Kruse and Kirsten Raun's team spent years solving amylin's clumping problem, and in 2021 published cagrilintide, a stable, lipidated, once weekly version. Russian endocrinology reviews describe amylin as the third pancreatic hormone alongside insulin and glucagon, and 2025 Russian work places cagrilintide at the heart of the next incretin combinations, including for people losing muscle as well as gaining fat.